Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open label, single-center study, in kidney transplant recipients with
stable renal function for 12 and 120 months after transplantation, that are in use use of
calcineurin inhibitors, azathioprine, and prednisone. The prevalence of left ventricular
hypertrophy will be investigated before and after conversion of azathioprine to everolimus.
This study will evaluate as primary objectives: the prevalence of left ventricular mass
hypertrophy in renal transplant recipients with azathioprine therapy. And assess the ability
of everolimus to reduce left ventricular mass after conversion from Azathioprine, using
sensitive methods such as MRI. And as secondaries objectives: Renal function (measured GFR)
at 3 and 6 and 12 months after conversion, number and severity of episodes of acute rejection
proven by biopsy, and the proteinuria at 3, 6 and 12 months after conversion.